These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27197195)

  • 21. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
    Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
    Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mTORC1 is a critical mediator of oncogenic Semaphorin3A signaling.
    Yamada D; Kawahara K; Maeda T
    Biochem Biophys Res Commun; 2016 Aug; 476(4):475-480. PubMed ID: 27246732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of PERK activity and eIF2α serine 51 phosphorylation by mTOR complex 1 elicits pro-oxidant and pro-death effects in tuberous sclerosis-deficient cells.
    Krishnamoorthy J; Tenkerian C; Gupta J; Ghaddar N; Wang S; Darini C; Staschke KA; Ghosh A; Gandin V; Topisirovic I; Kristof AS; Hatzoglou M; Simos G; Koromilas AE
    Cell Death Dis; 2018 Feb; 9(3):254. PubMed ID: 29449538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
    Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
    Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fisetin regulates obesity by targeting mTORC1 signaling.
    Jung CH; Kim H; Ahn J; Jeon TI; Lee DH; Ha TY
    J Nutr Biochem; 2013 Aug; 24(8):1547-54. PubMed ID: 23517912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glutaredoxin-1 promotes lymphangioleiomyomatosis progression through inhibiting Bim-mediated apoptosis via COX2/PGE2/ERK pathway.
    Feng Y; Li T; Li Y; Lin Z; Han X; Pei X; Zhang Y; Li F; Yang J; Shao D; Li C
    Clin Transl Med; 2023 Jul; 13(7):e1333. PubMed ID: 37478294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of mTORC1 renders cardiac protection against lipopolysaccharide.
    Li X; Jiang L; Lin S; He Y; Shen G; Cai Z; Ling M; Ni J; Zhang H; Zhang M
    Int J Clin Exp Pathol; 2014; 7(12):8432-42. PubMed ID: 25674207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mTORC1 inhibitors suppress meningioma growth in mouse models.
    Pachow D; Andrae N; Kliese N; Angenstein F; Stork O; Wilisch-Neumann A; Kirches E; Mawrin C
    Clin Cancer Res; 2013 Mar; 19(5):1180-9. PubMed ID: 23406776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.
    Teo T; Yu M; Yang Y; Gillam T; Lam F; Sykes MJ; Wang S
    Cancer Lett; 2015 Feb; 357(2):612-23. PubMed ID: 25527453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
    Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
    J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. mTORC1 Inhibition Corrects Neurodevelopmental and Synaptic Alterations in a Human Stem Cell Model of Tuberous Sclerosis.
    Costa V; Aigner S; Vukcevic M; Sauter E; Behr K; Ebeling M; Dunkley T; Friedlein A; Zoffmann S; Meyer CA; Knoflach F; Lugert S; Patsch C; Fjeldskaar F; Chicha-Gaudimier L; Kiialainen A; Piraino P; Bedoucha M; Graf M; Jessberger S; Ghosh A; Bischofberger J; Jagasia R
    Cell Rep; 2016 Apr; 15(1):86-95. PubMed ID: 27052171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
    Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
    Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y
    Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of (S)-4-isobutyloxazolidin-2-one as a novel leucyl-tRNA synthetase (LRS)-targeted mTORC1 inhibitor.
    Yoon S; Kim JH; Yoon I; Kim C; Kim SE; Koh Y; Jeong SJ; Lee J; Kim S; Lee J
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3038-3041. PubMed ID: 27209231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FIM-A, a phosphorus-containing sirolimus, inhibits the angiogenesis and proliferation of osteosarcomas.
    Liu WN; Lin JH; Cheng YR; Zhang L; Huang J; Wu ZY; Wang FS; Xu SG; Lin WP; Lan WB; Yang GX
    Oncol Res; 2013; 20(7):319-26. PubMed ID: 23879172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cell-penetrating ester of the neural metabolite lanthionine ketimine stimulates autophagy through the mTORC1 pathway: Evidence for a mechanism of action with pharmacological implications for neurodegenerative pathologies.
    Harris-White ME; Ferbas KG; Johnson MF; Eslami P; Poteshkina A; Venkova K; Christov A; Hensley K
    Neurobiol Dis; 2015 Dec; 84():60-8. PubMed ID: 25779968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mTORC1 Prevents Preosteoblast Differentiation through the Notch Signaling Pathway.
    Huang B; Wang Y; Wang W; Chen J; Lai P; Liu Z; Yan B; Xu S; Zhang Z; Zeng C; Rong L; Liu B; Cai D; Jin D; Bai X
    PLoS Genet; 2015 Aug; 11(8):e1005426. PubMed ID: 26241748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tuberous Sclerosis Complex Protein 2-Independent Activation of mTORC1 by Human Cytomegalovirus pUL38.
    Bai Y; Xuan B; Liu H; Zhong J; Yu D; Qian Z
    J Virol; 2015 Aug; 89(15):7625-35. PubMed ID: 25972538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repression of Mammalian Target of Rapamycin Complex 1 Inhibits Intestinal Regeneration in Acute Inflammatory Bowel Disease Models.
    Guan Y; Zhang L; Li X; Zhang X; Liu S; Gao N; Li L; Gao G; Wei G; Chen Z; Zheng Y; Ma X; Siwko S; Chen JL; Liu M; Li D
    J Immunol; 2015 Jul; 195(1):339-46. PubMed ID: 26026060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.